Is This Coronavirus Treatment Setting Investors Up for Failure?
Treatments haven't gotten the same attention as vaccines in the fight against COVID-19. Until President Trump was infected, most of the news was focused on which big pharma or biotech company would produce an effective vaccine first. Even the government's funding program, Operation Warp Speed (OWS), spent about 20 times the money on vaccines as it did on treatments.
Gilead Sciences (NASDAQ: GILD), along with several monoclonal antibody treatment makers, were thrust into the spotlight when President Trump was diagnosed with the virus. Although the company's antiviral drug, remdesivir, was given some of the credit for his speedy recovery, the World Health Organization (WHO) has held firm that there is no benefit to taking it. Now that Regeneron (NASDAQ: REGN) and Eli Lilly (NYSE: LLY) have received Emergency Use Authorization (EUA) from the U.S. Food & Drug Administration (FDA) for monoclonal antibody treatments, where does that leave Gilead?
Image source: Getty Images.
Source Fool.com
